Dialyzer reprocessing with peracetic/acetic acid linked to higher mortality rate -- JAMA study.
This article was originally published in The Gray Sheet
Executive Summary
AUTOMATED DIALYZER REPROCESSING CAN REDUCE PATIENT MORTALITY associated with dialyzer reuse, Harold Feldman, MD, University of Pennsylvania Medical Center, Philadelphia et al. comment in the Aug. 28 issue of The Journal of the American Medical Association. Analyzing the effect of dialyzer reuse on patient outcomes, the authors found that in free-standing dialysis clinics, manual reprocessing resulted in a 7% increase in mortality compared to automatic reprocessing. Automated reprocessing was associated with a "small" reduction in mortality rates in freestanding dialysis clinics, Feldman et al. say.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.